WO2003084566A3 - Proteins involved in the regulation of energy homeostasis - Google Patents

Proteins involved in the regulation of energy homeostasis Download PDF

Info

Publication number
WO2003084566A3
WO2003084566A3 PCT/EP2003/003747 EP0303747W WO03084566A3 WO 2003084566 A3 WO2003084566 A3 WO 2003084566A3 EP 0303747 W EP0303747 W EP 0303747W WO 03084566 A3 WO03084566 A3 WO 03084566A3
Authority
WO
WIPO (PCT)
Prior art keywords
regulation
energy homeostasis
proteins involved
energy
disorders
Prior art date
Application number
PCT/EP2003/003747
Other languages
French (fr)
Other versions
WO2003084566A2 (en
Inventor
Karsten Eulenberg
Thomas Haeder
Arnd Steuernagel
Guenter Broenner
Original Assignee
Develogen Ag
Karsten Eulenberg
Thomas Haeder
Arnd Steuernagel
Guenter Broenner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Develogen Ag, Karsten Eulenberg, Thomas Haeder, Arnd Steuernagel, Guenter Broenner filed Critical Develogen Ag
Priority to AU2003224062A priority Critical patent/AU2003224062A1/en
Publication of WO2003084566A2 publication Critical patent/WO2003084566A2/en
Publication of WO2003084566A3 publication Critical patent/WO2003084566A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1252—DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/033—Rearing or breeding invertebrates; New breeds of invertebrates
    • A01K67/0333—Genetically modified invertebrates, e.g. transgenic, polyploid
    • A01K67/0337—Genetically modified Arthropods
    • A01K67/0339—Genetically modified insects, e.g. Drosophila melanogaster, medfly
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Husbandry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)

Abstract

The present invention discloses novel uses for energy homeostasis regulating proteins and polynucleotides encoding these in the diagnosis, study, prevention, and treatment of metabolic diseases and disorders.
PCT/EP2003/003747 2002-04-10 2003-04-10 Proteins involved in the regulation of energy homeostasis WO2003084566A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003224062A AU2003224062A1 (en) 2002-04-10 2003-04-10 Proteins involved in the regulation of energy homeostasis

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP02008037 2002-04-10
EP02008037.0 2002-04-10
EP02008509 2002-04-15
EP02008509.8 2002-04-15
EP02009068.4 2002-04-23
EP02009068 2002-04-23

Publications (2)

Publication Number Publication Date
WO2003084566A2 WO2003084566A2 (en) 2003-10-16
WO2003084566A3 true WO2003084566A3 (en) 2004-04-01

Family

ID=28794670

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/003747 WO2003084566A2 (en) 2002-04-10 2003-04-10 Proteins involved in the regulation of energy homeostasis

Country Status (2)

Country Link
AU (1) AU2003224062A1 (en)
WO (1) WO2003084566A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023100A2 (en) * 1998-10-22 2000-04-27 Curagen Corporation Genes and proteins predictive and therapeutic for renal disease and associated disorders
WO2002005810A1 (en) * 2000-07-18 2002-01-24 Joslin Diabetes Center Modulation of nitric oxide synthase by pkc

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023100A2 (en) * 1998-10-22 2000-04-27 Curagen Corporation Genes and proteins predictive and therapeutic for renal disease and associated disorders
WO2002005810A1 (en) * 2000-07-18 2002-01-24 Joslin Diabetes Center Modulation of nitric oxide synthase by pkc

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KUEBLER D ET AL: "Genetic suppression of seizure susceptibility in Drosophila", JOURNAL OF NEUROPHYSIOLOGY 2001 UNITED STATES, vol. 86, no. 3, 2001, pages 1211 - 1225, XP002248167, ISSN: 0022-3077 *
SCHOMBERG L ET AL: "Human TRH-degrading ectoenzyme, cDNA cloning, functional expression, genomic structure and chromosomal assignment", EUROPEAN JOURNAL OF BIOCHEMISTRY, BERLIN, DE, vol. 265, 1999, pages 415 - 422, XP002199510, ISSN: 0014-2956 *

Also Published As

Publication number Publication date
AU2003224062A1 (en) 2003-10-20
WO2003084566A2 (en) 2003-10-16

Similar Documents

Publication Publication Date Title
HK1087398A1 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
WO2007127505A3 (en) Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
WO2004009034A3 (en) Thiomolybdate analogues and uses thereof
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
EP1765388B8 (en) Combination therapy for preventing or treating alzheimer's disease, and kit therefor
WO2004006858A3 (en) Compounds, compositions, and methods employing same
EP2213684A3 (en) Nogo-a antibodies for the treatment of Alzheimer disease
AP2005003350A0 (en) 3-(3,5-dioxo-4,5-dihydro-3H-(1,2,4) triazin-2-yl)-benzamide derivatives as p2X7 -inhibitors for the treatment of inflammatory diseases.
WO2006044860A3 (en) Thiadiazole compounds and methods of use
WO2002076494A3 (en) USE OF CYTOKINES OF THE TGF-β SUPERFAMILY FOR THE TREATMENT AND DIAGNOSIS OF SKIN RELATED DISORDERS
WO2006028492A3 (en) hC1Q/TNF7 AND USES THEREOF
WO2003039453A3 (en) Novel benzoyl peroxide compositions for the treatment of dermatological disorders and methods for their use
WO2004035082A3 (en) Proteins involved in the regulation of energy homeostasis
WO2003092715A3 (en) Proteins involved in the regulation of energy homeostasis
WO2004020465A3 (en) Proteins involved in the regulation of energy homeostasis
WO2004016641A3 (en) Proteins involved in the regulation of energy homeostasis
WO2004047855A3 (en) Proteins involved in the regulation of energy homeostasis
WO2004054601A3 (en) Fwd, pp2c1, adk3, cg3860, cdk4, cg7134, eip75b involved in the regulation of energy homeostasis
WO2004064856A3 (en) Proteins involved in the regulation of energy homeostasis
WO2003084566A3 (en) Proteins involved in the regulation of energy homeostasis
WO2004002513A3 (en) Proteins involved in the regulation of energy homeostasis
WO2003066086A3 (en) Proteins involved in the regulation of energy homeostatis
WO2003026566A3 (en) Atlastin
WO2003103704A3 (en) L(2)44 dea, wunen-2, grapes, cg2221, cg1172, rutabaga, cg11940, facl involved in the regulation of energy homeostasis
WO2005022164A3 (en) Diagnostics and therapeutics for diseases associated with kallikrein 8 (klk8)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP